Press-release for stocks related to regulatory

approved tags : Regulatory

save search

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Published: 2024-04-23 (Crawled : 07:00) - biospace.com/
IBRX | $4.82 -12.2% -14.02% 7.4M

Manufacturing

| -8.63% | O: 16.59% H: 0.65% C: -10.73%
il-15 anktiva fda agonist approval bladder cancer for

FASENRA approved for treatment of children aged 6 to 11 with severe asthma
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
AZNCF | News | $135.35 -3.53% -4.19% 0

Health Technology

| -0.66% | O: 1.47% H: 1.16% C: -1.27%
AZN | News | $71.2 0.49% 0.46% 300K

Health Technology

| 5.29% | O: 3.34% H: 0.27% C: -0.62%
children approved treatment for

Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
VVOS | $2.57 -3.02% -2.71% 75K

Health Technology

| -15.18% | O: -0.33% H: 13.91% C: -8.77%
approval care for medical

European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Published: 2024-04-03 (Crawled : 08:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M

Health Technology

| -7.36% | O: -0.08% H: 0.3% C: -0.99%
reblozyl anemia approval treatment

FDA Approves New Treatments for Two Rare Diseases
Published: 2024-03-27 (Crawled : 13:30) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310

Health Technology

| -5.96% | O: -0.26% H: 0.0% C: 0.0%
PRGO | $31.23 2.43% 0.0% 960K

Health Technology

| 1.4% | O: 0.84% H: 1.48% C: 1.29%
JNJ | News | $148.53 -0.69% 0.18% 7.5M

Health Technology

| -4.81% | O: 0.3% H: 0.0% C: 0.0%
ABT | News | $106.89 -0.65% -0.09% 4.2M

Health Technology

| -3.21% | O: 1.48% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| -3.57% | O: 1.06% H: 0.0% C: 0.0%
fda rare

COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024: Glo...
Published: 2024-03-27 (Crawled : 13:30) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310

Health Technology

| -5.96% | O: -0.26% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| -3.57% | O: 1.06% H: 0.0% C: 0.0%
copd potential market

FDA Approves Takeda’s Iclusig for Type of Leukemia, Idorsia’s Hypertension Drug
Published: 2024-03-21 (Crawled : 13:30) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310

Health Technology

| -0.92% | O: 0.14% H: 0.24% C: 0.24%
PRGO | $31.23 2.43% 0.0% 960K

Health Technology

| -0.22% | O: 0.0% H: 1.6% C: 0.89%
JNJ | News | $148.53 -0.69% 0.18% 7.5M

Health Technology

| -4.78% | O: -0.03% H: 0.0% C: 0.0%
ABT | News | $106.89 -0.65% -0.09% 4.2M

Health Technology

| -5.1% | O: -0.56% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| 0.26% | O: 0.3% H: 0.0% C: 0.0%
fda drug iclusig hypertension

Madrigal’s Rezdiffra, BMS’s Breyanzi Lead Week of Landmark FDA Approvals
Published: 2024-03-15 (Crawled : 15:00) - biospace.com/
PRGO | $31.23 2.43% 0.0% 960K

Health Technology

| 1.17% | O: -0.62% H: 0.59% C: -1.01%
JNJ | News | $148.53 -0.69% 0.18% 7.5M

Health Technology

| -7.87% | O: -1.58% H: 0.0% C: 0.0%
ABT | News | $106.89 -0.65% -0.09% 4.2M

Health Technology

| -10.96% | O: -5.53% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| -2.03% | O: -0.02% H: 0.0% C: 0.0%
fda breyanzi week

FDA Decisions: BeiGene Secures Record Fifth Oncology Approval for Brukinsa
Published: 2024-03-08 (Crawled : 18:00) - biospace.com/
PRGO | $31.23 2.43% 0.0% 960K

Health Technology

| 5.19% | O: 0.98% H: 3.17% C: 0.9%
JNJ | News | $148.53 -0.69% 0.18% 7.5M

Health Technology

| -7.43% | O: -0.68% H: 0.0% C: 0.0%
ABT | News | $106.89 -0.65% -0.09% 4.2M

Health Technology

| -11.0% | O: 0.58% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| -1.36% | O: -0.08% H: 0.0% C: 0.0%
fda brukinsa approval

FDA Decisions: First Frontline Pancreatic Cancer Treatment Approved in More t...
Published: 2024-02-15 (Crawled : 17:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310

Health Technology

| 3.92% | O: 1.16% H: 1.48% C: 0.89%
PRGO | $31.23 2.43% 0.0% 960K

Health Technology

| -1.05% | O: 0.67% H: 2.06% C: 1.86%
JNJ | News | $148.53 -0.69% 0.18% 7.5M

Health Technology

| -5.2% | O: -0.19% H: 1.6% C: 1.24%
ABT | News | $106.89 -0.65% -0.09% 4.2M

Health Technology

| -4.61% | O: 0.41% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| 3.91% | O: 1.86% H: 0.0% C: 0.0%
fda first approved cancer pancreatic treatment

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Published: 2024-02-13 (Crawled : 09:00) - biospace.com/
VRTX | $400.76 -1.03% -1.06% 810K

Health Technology

| -4.25% | O: -0.28% H: 0.49% C: -0.32%
first disease cell treatment

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device Company’s International Reach Expanding with Latest Regulatory Approval
Published: 2024-02-08 (Crawled : 23:00) - biospace.com/
NXL | $1.42 -12.62% -8.33% 77K

| 345.14% | O: 4.26% H: 0.0% C: -8.87%
device approval reach international technology

FDA Decisions: Takeda's Immunoglobulin Therapy Approved for CDIP
Published: 2024-02-02 (Crawled : 17:00) - biospace.com/
PRGO | $31.23 2.43% 0.0% 960K

Health Technology

| -3.25% | O: -0.53% H: 1.28% C: 0.53%
JNJ | News | $148.53 -0.69% 0.18% 7.5M

Health Technology

| -6.28% | O: -0.15% H: 0.0% C: 0.0%
ABT | News | $106.89 -0.65% -0.09% 4.2M

Health Technology

| -6.64% | O: -0.57% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| -2.09% | O: -0.93% H: 0.0% C: 0.0%
fda approved therapy

FDA Decisions: J&J's Bladder Cancer Drug Wins Full Approval
Published: 2024-01-22 (Crawled : 14:30) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310

Health Technology

| -7.4% | O: 1.71% H: 0.0% C: -0.15%
PRGO | $31.23 2.43% 0.0% 960K

Health Technology

| -5.62% | O: 0.36% H: 2.11% C: 1.29%
JNJ | News | $148.53 -0.69% 0.18% 7.5M

Health Technology

| -7.99% | O: 0.6% H: 0.0% C: 0.0%
ABT | News | $106.89 -0.65% -0.09% 4.2M

Health Technology

| -6.18% | O: 0.88% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| -7.41% | O: -0.21% H: 0.0% C: 0.0%
fda drug approval bladder cancer

FDA Decisions: Casgevy's Surprise Early Approval and Another Nod for Takeda's...
Published: 2024-01-17 (Crawled : 17:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310

Health Technology

| -9.53% | O: -1.83% H: 0.0% C: 0.0%
PRGO | $31.23 2.43% 0.0% 960K

Health Technology

| -5.36% | O: -0.76% H: 0.73% C: -0.06%
JNJ | News | $148.53 -0.69% 0.18% 7.5M

Health Technology

| -8.51% | O: -1.02% H: 0.0% C: 0.0%
ABT | News | $106.89 -0.65% -0.09% 4.2M

Health Technology

| -5.81% | O: 0.12% H: 0.77% C: 0.27%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| -8.18% | O: 0.45% H: 0.06% C: -0.5%
fda approval

FDA Decisions: AstraZeneca and Ionis Gain Approval for Self-Administered hATT...
Published: 2023-12-22 (Crawled : 14:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310

Health Technology

| -1.89% | O: 3.66% H: 0.0% C: -0.12%
PRGO | $31.23 2.43% 0.0% 960K

Health Technology

| -0.57% | O: -0.06% H: 1.21% C: 0.99%
JNJ | News | $148.53 -0.69% 0.18% 7.5M

Health Technology

| -3.5% | O: 1.09% H: 0.0% C: 0.0%
ABT | News | $106.89 -0.65% -0.09% 4.2M

Health Technology

| -0.34% | O: 1.52% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| -2.64% | O: 1.03% H: 0.0% C: 0.0%
fda approval astrazeneca

IceCure's ProSense® Deepens Regulatory Approval in India
Published: 2023-11-29 (Crawled : 19:00) - biospace.com/
ICCM | $1.22 0.82% 94K

Manufacturing

| Email alert Add to watchlist
prosense approval india

FDA Approvals: Lilly Steps Up Obesity Game and Takeda's Big Week
Published: 2023-11-10 (Crawled : 14:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310

Health Technology

| 2.54% | O: -1.28% H: 0.0% C: 0.0%
PRGO | $31.23 2.43% 0.0% 960K

Health Technology

| 11.18% | O: 0.46% H: 1.06% C: 0.64%
JNJ | News | $148.53 -0.69% 0.18% 7.5M

Health Technology

| -1.26% | O: -1.24% H: 0.0% C: 0.0%
ABT | News | $106.89 -0.65% -0.09% 4.2M

Health Technology

| 12.73% | O: -0.8% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| 2.67% | O: -0.32% H: 0.0% C: 0.0%
fda obesity week

BioMarin Scores Expanded Approval for Dwarfism Treatment; Dupixent Suffers Ra...
Published: 2023-10-23 (Crawled : 15:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310

Health Technology

| -8.96% | O: 0.73% H: 0.0% C: -0.48%
PRGO | $31.23 2.43% 0.0% 960K

Health Technology

| 4.69% | O: -0.44% H: 0.08% C: -2.05%
JNJ | News | $148.53 -0.69% 0.18% 7.5M

Health Technology

| -2.75% | O: 0.28% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| -9.37% | O: -0.69% H: 0.0% C: 0.0%
dupixent approval

UCB Scores Two FDA Approvals; Intellia Makes Gene Editing History
Published: 2023-10-20 (Crawled : 12:30) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310

Health Technology